Business
MCAP: Strong growth in life science through buy & build, with 19% sales and 29% EBITA CAGR
MCAP: Strong growth in life science through buy & build, with 19% sales and 29% EBITA CAGR
About this update from Medcap Ab
A diversified life science group with strong growth, MedCap focuses on assistive tech, medtech, and specialty pharma, achieving a 19% sales CAGR and 29% EBITA CAGR over five years. The company pursues a buy & build strategy, prioritizing sustainability, scalable businesses, and long-term value creation.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.